Table II.

Characteristics and treatment outcomes of patients on ART (>6 months) according to HIV type in Khar Clinic (n=443)

Variable	HIV-1a n (%)	HIV-2 n (%)	P valuebc	HIV-1&2 n (%)	P valuebd
Total	414	25	-	4	-
Sex
Females	231 (56)	11 (44)	0.2	0 (0)	-
Males	164 (40)	14 (66)	0.01	4 (100)	0.2
TG	19 (4)	0		0	-
Age (yr)
<15	18 (4)	0 (0)	-	0 (0)
15-29	78 (19)	15 (60)	<0.001	4 (100)
30-44	274 (66)	10 (40)	<0.001	0 (0)
45+	44 (11)
Age, yr, median (IQR)	37 (33-43)	45 (41-49)	0.01	44 (39-43)	0.15
WHO clinical stage
Stage I or II (CD4<250 cells/µl)	185 (45)	5 (20)	0.01	0 (0)	-
Stage III	128 (31)	12 (48)	0.07	2 (50)	0.7
Stage IV	101 (21)	8 (32)	0.19	2 (50)	0.8
CD4 count, (cells/µl)
<50	73 (18)	3 (12)	0.6	0 (0)	-
50-199	244 (59)	21 (84)	0.01	4 (100))	0.2
200-349	87 (21)	1 (4)	0.03	0 (0)	-
≥350	10 (2)	0 (0)	-	0 (0)	-
Median (IQR)	189 (72-262)	96 (73-111)	0.03	114 (79-150)	0.4
ART regimen
2 NRTIs + 1 NNRTI	334 (81)	0 (0)	-	0 (0)
3 NRTIs	5 (1)	10 (40)	< 0.001	0 (0)
2 NRTIs + Pls	75 (18)	15 (60)	< 0.001	4 (100)	0.8
ART outcomes
Alive on ART	333 (80)	25 (100)	-	2 (50)	-
Dead	36 (9)	0 (0)		2 (50)
Lost to follow up	31 (8)	0 (0)		0 (0)
Transferred out	14 (3)	0 (0)		0 (0)

IQR, interquartile range; ART, antiretroviral therapy; WHO, World Health Organization; NRTI, nucleoside reverse transcriptase inhibitors;NFV, nelfinavir; LPV/r, lopinavir/ritonavir; IDV, indinavir; NNRTI, non-nucleoside reverse transcriptase inhibitors;

^a1unknown outcome for HIV-1;

^bX² test for categorical variables and Wilcoxon rank-sum test for continuous variables;

^cComparing HIV-1 with HIV- 2;

^dComparing HIV-1with HIV-1 & 2